Researchers seek development of drug therapies and technologies to assist in achieving additional time in glucose target range and less hypoglycemia.

First oral GLP-1 agonist undergoing Phase 3 trials shows significant benefits managing type 2 diabetes.

Study looks at convenient once-weekly GLP-1 that can reduce chances of heart attacks and strokes.

Recommendations place special emphasis on youth newly diagnosed with diabetes.

By Sheri R. Colberg, PhD, FACSM As discussed in an earlier column this year (June 2018), many insulin users have chosen to go “low-carb” to better manage diabetes, which may or may not impact how well they perform in athletic events. How do many athletes with diabetes who swear by …

What is your top concern when prescribing SGLT-2 inhibitors to patients with diabetes?

- Amputation risk
- Infection risk
- Kidney risk
- Price

Follow the link and see how you compare to your colleagues.

Which of the following is an important consideration when giving a post-meal insulin bolus with the aid of CGM-based trend arrows dosing in order to avoid hypoglycemia in persons using multiple daily insulin therapy?

A. Always consider using the full dose suggested by calculations based on the correction factor and target glucose.
B. Give ~50% of the calculated insulin dose (using the correction factor and target glucose) to adjust for active insulin (insulin on board).
C. Use ~25% of the calculated insulin dose (using the correction factor and target glucose) to adjust for active insulin (insulin on board).
D. Use 75% of the calculated insulin dose (using the correction factor and target glucose) to adjust for active insulin (insulin on board).
E. Another insulin dose should never be given after eating.

Follow the link for the answer.

The 122nd Annual Meeting of the American Academy of OphthalmologyThe annual meeting of the American Academy of Ophthalmology was held from Oct. 27 to 30 in Chicago and attracted approximately 6,000 participants from around the world, including ophthalmologists, optometrists, opticians, and other eye health care professionals. The conference featured presentations …

Based on data from 40 jurisdictions, increase from 5.2 to 5.6 percent in GDM from 2012 to 2016

This GLP-1 Agonist Medications Chart outlines the latest GLP-1 medications approved by the FDA for diabetes treatment and the differences and similarities between them. Print out this chart and post in your office as a handy reference for your staff and patients alike. The chart is in PDF format. Use this link to download: GLP-1 Agonist Medications Chart